UNSPSC 51282304: Erythromycin

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin but generally known as erythromycin, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules Erythromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG.

UNSPSC 51282304 Erythromycin is a Commodity code that in recent state and local activity covers a broader range of pharmaceutical and medical supplies procurement than the code name alone suggests. Recent solicitations under this code show state and local governments purchasing naloxone, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing arrangements, and establishing direct-to-manufacturer prescription programs. The issuing bodies include county health departments, city fire and rescue services, state health and human services agencies, and state purchasing alliances operating on behalf of multiple member jurisdictions. Work solicited ranges from emergency medical consumables and cardiac monitoring supplies to bulk generic pharmaceutical contracting with established distribution channels through authorized wholesalers and direct manufacturer relationships.

Geographic activity spans Florida, Texas, Minnesota, and participating states within cooperative purchasing alliances such as MMCAP. Recent representative opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives; the City of Tampa's Bid 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a sheltered-market set-aside for certified Small Local Business Enterprises and a 5 percent SLBE bid discount; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs with self-insured employers and state agencies; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026, with pricing weighted 75 percent on competitiveness and responses due through the ePro system in CSV format.